Cargando…

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines

HER2-positive breast tumors are associated with a high risk of brain relapse. HER3 is thought to be an indispensible signaling substrate for HER2 (encoded by ERBB2) and is induced in breast cancer-brain metastases, though the molecular mechanisms by which this oncogenic dimer promotes the developmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Momeny, Majid, Saunus, Jodi M., Marturana, Flavia, McCart Reed, Amy E., Black, Debra, Sala, Gianluca, Iacobelli, Stefano, Holland, Jane D., Yu, Dihua, Da Silva, Leonard, Simpson, Peter T., Khanna, Kum Kum, Chenevix-Trench, Georgia, Lakhani, Sunil R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414164/ https://www.ncbi.nlm.nih.gov/pubmed/25668816

Ejemplares similares

High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations
por: Johnston, Rebecca L., et al.
Publicado: (2016)

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
por: Lakhani, Sunil R, et al.
Publicado: (2010)

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
por: Bessette, Darrell C., et al.
Publicado: (2015)

Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context
por: Saunus, Jodi M., et al.
Publicado: (2017)

Clinicopathologic significance of nuclear HER4 and phospho-YAP(S(127)) in human breast cancers and matching brain metastases
por: Kalita-de Croft, Priyakshi, et al.
Publicado: (2020)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer
por: Al-Ejeh, Fares, et al.
Publicado: (2014)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
por: Da Silva, Leonard, et al.
Publicado: (2010)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Molecular Aspects of Breast Cancer Metastasis to the Brain
por: Saunus, Jodi M., et al.
Publicado: (2011)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers
por: McCart Reed, Amy E, et al.
Publicado: (2019)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer
por: Saunus, Jodi M., et al.
Publicado: (2022)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy
por: Liu, Chao, et al.
Publicado: (2014)

NDRG1 in Cancer: A Suppressor, Promoter, or Both?
por: Joshi, Vaibhavi, et al.
Publicado: (2022)

Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer
por: Adwal, Alaknanda, et al.
Publicado: (2020)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation
por: Pan, Min-Hsiung, et al.
Publicado: (2011)

An Update on the Molecular Pathology of Metaplastic Breast Cancer
por: McCart Reed, Amy E, et al.
Publicado: (2021)

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
por: Hancock, Janelle L., et al.
Publicado: (2023)

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype
por: McCart Reed, Amy E., et al.
Publicado: (2021)

Rad51 supports triple negative breast cancer metastasis
por: Wiegmans, Adrian P, et al.
Publicado: (2014)

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer
por: Spurdle, Amanda B, et al.
Publicado: (2002)

Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics
por: Reed, Amy E McCart, et al.
Publicado: (2015)

Androgen receptor transcriptional activity is required for heregulin-1β–mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase
por: Jathal, Maitreyee K., et al.
Publicado: (2023)

BCoR-L1 variation and breast cancer
por: Lose, Felicity, et al.
Publicado: (2007)

Correction: BCoR-L1 variation and breast cancer
por: Lose, Felicity, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2ce4slf0dh4caiftci28pfhqnd